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Deposition of fibrin in the brain and central nervous system occurs upon injury or disease. 
This process unmasks a conserved cryptic epitope of fibrin that activates microglia; 
blocking this interaction can limit inflammation and neurotoxicity. 
 
The clotting factor fibrin plays a crucial role in blood coagulation. Akassoglou and colleagues 
define a novel specific role of fibrin in neurodegeneration1, where important unmet medical 
needs exist for neurodegenerative and neuroinflammatory diseases like Alzheimer's disease 
(AD) and multiple sclerosis (MS). Only symptomatic therapies are available for AD, and, 
although MS can be treated with several immunomodulatory drugs, there is no remedy for 
the processes that drive nerve cell damage, demyelination and clinical disability at the later 
stages, most notably radical-mediated stres2. Akassoglou and colleagues1 provide an elegant 
approach that could lead into an urgently needed disease-modifying therapy for both AD 
and MS2.  
The solution of the Akassoglou group and collaborators derives from a long interest in 
deciphering how factors of the coagulation system contribute to a range of pathologies in 
the brain2. Blood clotting involves a series of well-orchestrated cellular and molecular steps 
that lead to temporally closing a ruptured vessel and, starting from blood components 
contacting the injured vessel endothelium, changes in platelets, and activation of the so-
called extrinsic pathway of the coagulation cascade. The latter refers to activation of several 
enzymes beginning with prothrombin, which is produced in the liver and activated to 
thrombin by tissue factor. The following intermediate steps lead to activation of coagulation 
factor X and then cleavage of the plasma protein fibrinogen to fibrin. The final common 
pathway results in closing the damaged vessel by a polymerized fibrin clot.   
Physiological functions of coagulation products are, however, not only clotting, but 
also trapping bacteria, direct antimicrobial effects, tissue remodeling, and innate immune 
activation3-5. These functions have received overall less attention. Yet another facet of the 
coagulation system has been brought to our attention by the work of Akassoglou and 
others5–7. It was already observed several decades ago that fibrin deposition frequently 
occurs in the brain tissue of patients suffering from neurodegenerative and 
neuroinflammatory conditions such as AD and MS6,7, but also in the experimental model of 
the latter, experimental autoimmune encephalomyelitis (EAE)8. The damaging role of 
fibrin(ogen) leakage in these conditions was underscored by the tight relationship of tissue 
fibrin and clinical severity of EAE, worsening EAE when the gene encoding tissue 
plasminogen activator (tPA) is deleted, and several other studies. Previous studies over 
three decades ago showed that fibrin deposition can be targeted by a synthetic inhibitor of 
plasminogen activator9.  
It is now clear that the vascular system and brain engage in intense crosstalk4,5. 
Beyond supplying blood and oxygen cerebrovascular interactions are involved in 
maintaining endothelial cell homeostasis, synaptic activity and neurogenesis in the adult 
organism among others. Vessel damage on the other hand is involved in a host of 
pathologies ranging from bacterial meningitis to glioblastoma and AD. Whenever blood 
components leak into brain tissue, fibrin deposition then interacts through receptor-ligand 
interactions and signaling steps involving MAPK and NF-κB with resident microglia and 
invading immune cells. Immune cell-derived cytokines like tumor necrosis factor (TNF) 
enhance fibrin formation and coagulation5.  
The study by Akassoglou and colleagues in this issue expands existing knowledge and 
lays the ground for a new therapeutic strategy1. It shows that fibrin interacts via a cryptic 
epitope, fibrin γ377-395, which is only exposed after fibrin polymerization, with the CD11b 
I-domain of complement receptor 3 (CR3) of microglia and macrophages and activates these 
innate immune cells (Fig. 1). They reasoned that a monoclonal antibody (mAb) that binds to 
this cryptic epitope, but not the γ400-411 site of fibrin, which mediates fibrin 
polymerization, should affect innate immune activation but not coagulation. By screening 
mAbs for differential binding to γ377-395, but not the γ400-411 epitope and another cryptic 
epitope, they identified mAb 5B8, which fulfils these criteria and binds with high affinity to 
the γ377-395 site only. Subsequent transcriptomics experiments demonstrate that fibrin 
binding to CR3 results in upregulation of a number of proinflammatory genes, among them 
Ncf4, an important component of the NADPH oxidase (Nox2) complex, which has been 
implicated in stroke and neurodegenerative diseases10. 5B8 inhibits microglia activation and 
the NADP oxidase pathway and prevents the release of reactive oxygen species (ROS). The 
potential neuroprotective effects were confirmed in co-cultures of fibrin-activated 
macrophages and neurons, where 5B8 reduced the damage and loss of neurons. These data 
were corroborated by testing 5B8 in three EAE models. 5B8 reduced the clinical signs and 
inhibited the accumulation of microglia and infiltration of macrophages in the spinal cord, 
but did not affect peripheral adaptive immune responses.  
Finally, Akassoglou and colleagues report the therapeutic potential of 5B8 in a model 
of AD1, the 5XFAD mouse, in which AD-mutant forms of human amyloid precursor protein 
and presenilin are overexpressed in neurons. Fibrin deposition in the brain of 5XFAD mice 
progressively accumulates from 3 months onward. Systemic administration of 5B8 
interestingly reaches the brain and sites of plaque formation and reduces both microglia 
activation and the loss of cholinergic neurons, a hallmark of AD. Transcriptome analysis of 
the brain cortex in 5B8-treated 5XFAD mice demonstrated that 5B8 preferentially 
suppresses five immune pathways, most notably a hub of genes belonging to the 
complement pathway, i.e. Tyrobp (also known as Dap12), C4b and C1q. Tyrobp codes for a 
coreceptor of CD11b and TREM2, another molecule that has been implicated in AD11.  
 What are the possible implications of these observations? In MS, selectively targeting 
oxidative stress and the so-called neurodegenerative aspects by 5B8 appears very 
attractive, since there is no therapy for these yet. Similarly in AD, complement factors are 
not only among the major risk genes12, but fibrin deposition and innate immune activation 
at the sites of amyloid plaques are considered important contributors to the progressive 
loss of nerve cells. So far, only the symptoms of AD can be treated by improving cholinergic 
nerve function, and while many compounds are in development, several have failed already 
and none directly targets the fibrin-mediated immune activation. The fact that 5B8 
penetrates the blood-brain-barrier, does not affect blood clotting, and leaves other 
pathways of innate immune activation and adaptive immunity seemingly intact, while 
inhibiting a core pathomechanism in MS, AD and other (neuro)inflammatory conditions 
such as stroke and rheumatoid arthritis, indicate that it could be a very interesting and 
novel approach to treat these diseases. Due to the many differences between rodents and 
humans, for example with respect to immune function13, a note of caution is warranted, 
and the data should be validated in human systems. Furthermore, interactions of a fibrin γC 
peptide truncated at position 399 have been shown to inhibit T cell activation14 and, on the 
other hand, fibrin aids in the host defense against bacteria via both innate and T cell-
mediated mechanisms15. Targeting a specific site of fibrin that separates different functions 
of this pleiotropic mediator therefore holds great promise, but the effects of 5B8 could be 
even broader than indicated by the study of Akassoglou and colleagues1 and should be 
followed carefully during clinical development for effects and adverse events.  
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Figure 1.  
The coagulation system and fibrin fulfill pleiotropic roles in biology besides coagulation (a, 
left), and numerous pathologies result from perturbations of their interplay (a, right). The 
ribbon model of the fibrin molecule (b) highlights the amino acid positions that are relevant 
for fibrin polymerization (γ400-411), the ones to which mab 5B8 binds (γ377-395), which 
blocks interactions with complement receptor 3 and activation of the NADP oxidase 
pathway as shown by Akassoglou and colleagues1, and finally another cryptic epitope (γ190-
202), which was employed for control purposes in the antibody screening strategy.  

